Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 05/05/22
Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022Business Wire • 05/02/22
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/10/22
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business UpdateBusiness Wire • 03/09/22
Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)Zacks Investment Research • 03/02/22
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022Business Wire • 03/02/22
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare ConferenceBusiness Wire • 02/09/22
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate MilestonesBusiness Wire • 01/11/22
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022Business Wire • 01/04/22
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021Business Wire • 12/13/21
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual MeetingBusiness Wire • 12/06/21
Moore Kuehn, PLLC Encourages Investors of Mirum Pharmaceuticals, Inc. to Contact Law FirmNewsfile Corp • 11/30/21
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/16/21
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 11/15/21
Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille SyndromeBusiness Wire • 11/15/21
Mirum Pharmaceuticals: Livmarli Approval Could Spark A Bull Run For This Young BiotechSeeking Alpha • 11/12/21
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021Business Wire • 11/08/21
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021Business Wire • 11/01/21
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille SyndromeBusiness Wire • 11/01/21
FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum PharmaBenzinga • 09/29/21